Category: Clinical Trials/Research/Emerging Treatments

For some patients, the future of mesothelioma cancer treatment may hinge on a pair of phase I clinical trials that opened earlier this year to study promising new drugs targeting specific genetic mutations. Precision medicine may finally be taking hold with malignant mesothelioma, clearing the path for significant, long-overdue advancements. The one-size-fits-all approach is fading. […]

The post Mesothelioma Clinical Trials Test Targeted Gene Therapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Late-stage patients with pleural mesothelioma have survived longer than anticipated — with good quality of life — in a phase I clinical trial studying the effectiveness of a novel combination treatment. The treatment involves galinpepimut-S, the latest targeted cancer vaccine also known as GPS, in combination with Opdivo, a popular immunotherapy drug. Memorial Sloan Kettering […]

The post Novel Clinical Trial Helping Late-Stage Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Over the years, I have “collected” many families affected by the BAP1 cancer syndrome, a novel medical condition we discovered in 2011. Pathogenic germline mutations, most of them BAP1 mutations, are estimated to be found in 10% of all those diagnosed with mesothelioma. BAP1 germline mutations occur in people born with only one functioning copy […]

The post Carbone: Building the Guide to BAP1 Mutation in Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Future treatment of pleural mesothelioma cancer continued its move toward a more personalized, targeted approach with the latest results from a multi-center clinical trial involving tazemetostat, a novel protein inhibitor. Tazemetostat, also known as the brand name Tazverik, showed impressive effectiveness in a second line setting for patients with the BAP1 genetic mutation. The disease […]

The post Targeted Therapy Making Progress with Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The acclaimed MD Anderson Cancer Center in Houston is opening a phase II clinical trial involving a new immunotherapy drug aimed specifically at advanced, rare cancers, including both pleural and peritoneal mesothelioma. This single-institution clinical trial will be measuring the safety and effectiveness of vudalimab, also known as XmAb20717, which was designed by the California-based […]

The post New Mesothelioma Immunotherapy Clinical Trial Opens at MD Anderson appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Patients with peritoneal mesothelioma cancer can survive considerably longer if they are willing and able to undergo a second aggressive surgery following tumor recurrence. History has proven that an incentive for a repeat surgery is there. A recent 30-year retrospective review at Wake Forest Baptist Medical Center has shown how beneficial the combination of cytoreductive […]

The post Study Finds Benefits to Second Peritoneal Mesothelioma Surgery appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.